Related Experiment Video
Updated: Apr 27, 2026
06:32
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
6.1K
Secondary sarcoma of bone post-prostate brachytherapy: A case report
Allison Y Ye1, Jessica Conway1, Michael Peacock1
1Department of Radiation Oncology, Vancouver Cancer Centre, British Columbia Cancer Agency, Vancouver, BC;
Summary
This study reports a rare case of pelvic osteogenic sarcoma developing 6 years after prostate brachytherapy. The patient received chemotherapy, surgery, and radiation for this unexpected malignancy following iodine-125 implantation.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Brachytherapy is a common treatment for prostate cancer.
- Malignancies developing after brachytherapy are rare and underreported.
- Permanent iodine-125 ((125)I) implants are used for intermediate-risk prostate cancer.
Purpose of the Study:
- To report a rare case of osteogenic sarcoma following prostate brachytherapy.
- To highlight the potential for secondary malignancies after radiation treatment.
- To discuss the management of such rare complications.
Main Methods:
- A case report of a patient who developed osteogenic sarcoma post-brachytherapy.
- Details of the patient's treatment for prostate cancer using permanent (125)I implant.
- Description of the multimodal treatment for the secondary pelvic osteogenic sarcoma.
Main Results:
- Osteogenic sarcoma was diagnosed 6 years after permanent prostate brachytherapy.
- The patient underwent neoadjuvant chemotherapy.
- Limb-sparing surgical resection and postoperative radiation therapy were performed due to positive margins.
Conclusions:
- Secondary osteogenic sarcoma is a rare but potential complication of prostate brachytherapy.
- Multidisciplinary management is crucial for patients developing post-brachytherapy malignancies.
- Long-term surveillance may be necessary for patients treated with brachytherapy.
